SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

The Veil community is rallying around the project's focus on digital privacy and decentralization, often citing its multi-algorithm mining and staking capabilities as key differentiators. Investors are actively discussing the potential for a privacy-focused market surge, frequently highlighting the project's long-term utility alongside established privacy coins.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending as heightened speculation around a potential buyout and unconfirmed M&A rumors drive significant after-hours volume and price volatility. Community members are actively debating the legitimacy of these reports, with long-term shareholders analyzing historical valuation metrics and potential takeover scenarios while others speculate on the motivations behind recent unusual trading patterns.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl Capital is trending due to significant liquidity concerns following the restricted withdrawal access in its private credit funds, which has sparked investor anxiety over potential sector-wide fallout. The community is actively debating whether this represents an isolated incident or a broader 'canary in the coal mine' moment for private credit stability amidst rising default risks.

Roundhill ETF Trust - Roundhill Ether Covered Call Strategy ETF

oundhill Ether Covered Call Strategy ETF

Investors are closely monitoring YETH as the community debates its weekly distribution payouts versus the underlying volatility of Ethereum. While some traders leverage the fund for its income potential during range-bound market phases, others remain cautious due to concerns regarding NAV erosion and management performance.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DebtReliefBot is trending as investors rally around its narrative as an AI-generated project linked to the Grok wallet, fueling speculation about its potential for growth within the Base ecosystem. The community remains highly bullish, frequently discussing its low follower count as a sign of being early while emphasizing its unique connection to AI-driven token creation.

ARK ETF Trust - ARK Autonomous Technology & Robotics ETF

ARK Autonomous Technology & Robotics ETF

ARKQ is capturing investor attention as community members debate whether emerging robotics and 'embodied AI' infrastructure will take the tech sector's leadership baton this year. The ETF remains a focal point for discussion regarding portfolio rotation into automation themes, with sentiment driven by institutional buying activity and the sector's long-term growth potential.

Eaton Corp. Plc is a power management company, which provides energy-efficient solutions for electrical, hydraulic, and mechanical power. It operates through the following segments: Electrical Americas and Electrical Global; Aerospace, Vehicle, and eMobility. The Electrical Americas and Electrical Global segments engage in sales contracts for electrical components, industrial components, power distribution and assemblies, residential products, single and three phase power quality, wiring devices, circuit protection, utility power distribution, power reliability equipment, and service. The Aerospace segment supplies aerospace fuel, hydraulics, and pneumatic systems for commercial and military use. The Vehicle segment deals with the design, manufacture, marketing, and supply of drivetrain and powertrain systems and critical components that reduce emissions and improve fuel economy, stability, performance and safety of cars, light trucks and commercial vehicles. The eMobility segment designs, manufactures, markets, and supplies electrical and electronic components and systems that improve the power management and performance of both on-road and off-road vehicles. The company was founded in 1911 and is headquartered in Dublin, Ireland.

Eaton Corporation plc

Eaton Corporation is trending as a major beneficiary of the AI-driven data center expansion, with investors betting on its critical role in power infrastructure and cooling systems. The community is actively discussing its long-term growth as a core industrial leader while monitoring recent price action and technical setups following volatility in the sector.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

Investors are closely watching the ARK Innovation ETF as it experiences sharp volatility, with community members expressing polarized views on Cathie Wood's aggressive buying and selling patterns amid broader market rotation out of high-beta growth stocks. The ongoing discourse highlights concerns over the fund's long-term performance and its heavy exposure to volatile tech and crypto-linked assets, leading to intense debates between those betting on an innovation-led rebound and those skeptical of the fund's strategy.

Monero

Monero (XMR) is trending as the community debates its role as the premier privacy-focused asset, with active discussions focusing on its unique resistance to regulatory oversight compared to transparent chains. Enthusiasts view it as a long-term store of value and a hedge against institutional tracking, while detractors continue to characterize the asset through speculative or cynical lenses.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

Investors are flocking to NEOS Nasdaq 100 High Income ETF (QQQI) to capture high monthly yields while maintaining core exposure to the Nasdaq 100. Community discussion centers on the fund's competitive edge over peers due to its tax-efficient return-of-capital structure and active management strategy, with many users dollar-cost averaging into positions as a long-term retirement income play.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanguard Announces Share Splits for Five Equity Index ETFs

Vanguard Announces Share Splits for Five Equity Index ETFs Vanguard Announces Share Splits for Five Equity Index ETFs PR Newswire VALLEY FORGE, Pa., March 24, 2026 VALLEY FORGE, Pa., March 24, 2026...

Should Vanguard S&P 500 Growth Index Fund ETF Shares (VOOG) Be on Your Investing Radar?

<ul class="summary-bullets"><li>Patients treated with povetacicept also demonstrated a 77.4% reduction from baseline in serum galactose deficient IgA1, a critical, disease-specific biomarker for IgA nephropathy, the company added.</li><li>Vertex now expects to complete necessary submissions seeking approval for povetacicept in IgA Nephropathy by March.</li><li>The company has a priority review voucher which would allow it to reduce the review time from ten months to six, it added.</li></ul><p><br>Shares of Vertex Pharmaceuticals Incorporated (VRTX) rose as much as 7% after hours on Monday after the company announced positive 36-week data from its ongoing late-stage trial evaluating povetacicept in immunoglobulin A nephropathy.</p><p>IgA nephropathy or Berger’s disease is an autoimmune kidney disease occurring when immunoglobulin A (IgA) antibody clumps deposit in the kidney’s glomeruli, causing inflammation and damage.</p><h2 class="st-heading-2">Trial Takeaways</h2><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-week-36-interim-analysis-results">said</a> that patients treated with povetacicept on top of standard of care achieved a 52% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal. The reduction was consistent across subgroups, the company said. &nbsp;</p><p>Patients treated with povetacicept also demonstrated a 77.4% reduction from baseline in serum galactose deficient IgA1, a critical, disease-specific biomarker for IgA nephropathy, the company added.</p><p>Povetacicept was generally safe and well tolerated with a majority of adverse events (AEs) being mild to moderate. There were no serious adverse events or deaths, and no discontinuations due to infections, the company added.</p><h2 class="st-heading-2">Plans Ahead</h2><p>Vertex now expects to complete necessary submissions seeking approval for povetacicept in IgA Nephropathy by March. The company has a priority review voucher which would allow it to reduce the review time from ten months to six, it added.</p><p>If approved, the company expects to launch povetacicept in a low volume subcutaneous auto-injector delivered once every four weeks via at-home administration.</p><p>Other companies with FDA-approved drugs for IgA Nephropathy include Travere Therapeutics and Novartis.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around VRTX shares stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.</p><p><a href="https://stocktwits.com/symbol/VRTX">VRTX stock</a> has declined 8% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/voyg-shares-decline-on-double-q4-miss-despite-record-2025-backlog/cZdVUXLRIeI">VOYG Shares Decline On Double Q4 Miss Despite Record 2025 Backlog</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, Vertex Pharmaceuticals' logo is displayed on a smartphone screen in front of a stock chart. (Photo illustration by Cheng Xin/Getty Images)

VRTX Soars In Extended Hours After Experimental Drug Shows Positive Changes In Autoimmune Kidney Disease

The company said that patients treated with povetacicept achieved a 52.0% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal.

Equity

Should Vanguard S&P 500 Growth ETF (VOOG) Be on Your Investing Radar?

Growth ETF (VOOG) Hits New 52-Week High

VOOG hits a 52-week high amid tech-driven momentum and optimism over Fed rate cuts, hinting at more upside ahead.

Less-Than-Expected Inflation in July: Growth ETFs to Gain?

CPI rose less than expected, boosting hopes for Fed rate cuts and sparking interest in top growth-focused ETFs like VUG and RPG.



Three Rate Cuts Expected in 2025? ETFs in Focus 

Fed officials signal possible rate cuts this year, boosting the appeal of growth-focused ETFs amid slowing labor market trends. Tap ETFs like VUG, RPG and VOOG.

Fed to Cut Rates Ahead? Growth ETFs to Play 

Weak hiring and rising jobless rates have San Francisco Fed President Mary Daly eyeing Fed rate cuts. If the Fed cuts rates soon, growth ETFs like RPG and IVW could benefit.

Growth ETFs Set New Records, Brush Off Tariff Headwinds

Growth ETFs like MGK, VUG, IWY, IUSG, and SPYG and others hit fresh highs as investors shrug off tariff threats and chase AI-fueled momentum.


Vanguard Admiral Funds - Vanguard S&P 500 Growth ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

VOOG
Vanguard S&P 500 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest VOOG News

VOOGVanguard S&P 500 Growth ETF